Cargando…

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science

Although GLP-1 (glucagon like peptide-1) based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors) is currently playing a cornerstone role in the treatment of type 2 diabetes, dilemma does exist about some of its basic physiology. So far, we know that GLP-1 is secreted by the direct act...

Descripción completa

Detalles Bibliográficos
Autor principal:	Singh, Awadhesh Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287769/ https://www.ncbi.nlm.nih.gov/pubmed/25593851 http://dx.doi.org/10.4103/2230-8210.146881

Ejemplares similares

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
por: Arora, Tulika, et al.
Publicado: (2016)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion
por: Joo, Erina, et al.
Publicado: (2015)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE
por: LeValley, Stephanie L., et al.
Publicado: (2020)

Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure
por: Daghlas, Iyas, et al.
Publicado: (2021)

GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
por: Lin, Hua V., et al.
Publicado: (2018)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 receptor expression in the human eye
por: Hebsgaard, Josephine B., et al.
Publicado: (2018)

Chronic Elevation of Systemic Glucagon-Like Peptide-1 Following Surgical Weight Loss: Association with Nausea and Vomiting and Effects on Adipokines
por: Al-Rasheid, Noora, et al.
Publicado: (2014)

Incretin response in Asian type 2 diabetes: Are Indians different?
por: Singh, Awadhesh Kumar
Publicado: (2015)

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
por: Vesterinen, Tiina, et al.
Publicado: (2023)

Incretin Effect of Glucagon-Like Peptide 1 Receptor Agonist Is Preserved in Presence of ABCC8/SUR1 Mutation in β-Cell
por: Bourron, Olivier, et al.
Publicado: (2012)

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2010)

The incretin hormone glucagon‐like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage‐dependent potassium channel
por: Thiebaud, Nicolas, et al.
Publicado: (2016)

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia
por: Lietzau, Grazyna, et al.
Publicado: (2021)

Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor
por: Jones, Ben J., et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
por: Kang, Mi Yeon, et al.
Publicado: (2015)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1
por: Qu, Wei, et al.
Publicado: (2012)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs
por: Pratap-Singh, Anubhav, et al.
Publicado: (2023)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
por: Morais, Tiago, et al.
Publicado: (2023)

A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2020)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

MTORC1 inhibition drives crinophagic degradation of glucagon
por: Rajak, Sangam, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction
por: Chung, Jae-Wook, et al.
Publicado: (2021)

Increased biogenesis of glucagon-containing secretory granules and glucagon secretion in BIG3-knockout mice
por: Li, Hongyu, et al.
Publicado: (2015)

Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones
por: Olthof, Margreet R, et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_noa7e07oh1e3h4s40ukrkf366p